Inventor · disambiguated record
Tomoya Miyakawa
Also filed as: MIYAKAWA TOMOYA
15 granted patents·12 pending applications·11 citations·filing 2003–2022
88Inventor score
Top patents by PatentIndex Score
27 records- 0183US10842848B2Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion proteinCYTLIMIC INC·Filed 2016·Granted Nov 24, 2020·2 cites·8 claims
- 0283US8487076B1HLA-binding peptide, and DNA fragment and recombinant vector coding for said HLA-binding peptideMIYAKAWA TOMOYA·Filed 2005·Granted Jul 16, 2013·3 cites·4 claims
- 0381US9045531B2HLA-binding peptide, precursor thereof, and DNA fragment and recombinant vector coding for said HLA-binding peptideMIYAKAWA TOMOYA·Filed 2010·Granted Jun 2, 2015·3 cites·3 claims
- 0480US8324345B2HLA-binding peptide, precursor thereof, DNA fragment and recombinant vector encoding the sameMIYAKAWA TOMOYA·Filed 2007·Granted Dec 4, 2012·2 cites·7 claims
- 0577US9353151B2HLA-binding peptide, and DNA fragment and recombinant vector coding for said HLA-binding peptideNEC CORP·Filed 2013·Granted May 31, 2016·1 cites·4 claims
- 0676US12448413B2HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cellNEC CORP·Filed 2022·Granted Oct 21, 2025·0 cites·6 claims
- 0775US11304997B2HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cellCYTLIMIC INC·Filed 2019·Granted Apr 19, 2022·0 cites·5 claims
- 0872US11759518B2Medicine for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion proteinNEC CORP·Filed 2022·Granted Sep 19, 2023·0 cites·8 claims
- 0968US10875900B2Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cellsCYTLIMIC INC·Filed 2020·Granted Dec 29, 2020·0 cites·8 claims
- 1067US10590179B2Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cellsCYTLIMIC INC·Filed 2018·Granted Mar 17, 2020·0 cites·2 claims
- 1166US11491204B2Composition comprising poly I:C and LAG-3-IGG fusion proteinCYTLIMIC INC·Filed 2020·Granted Nov 8, 2022·0 cites·5 claims
- 1264US11618770B2MUC1-derived peptide, and pharmaceutical composition for treatment or prevention of cancer, immunity-inducing agent and method for manufacturing antigen presenting cell using sameNEC CORP·Filed 2020·Granted Apr 4, 2023·0 cites·4 claims
- 1361US11291718B2Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion proteinCYTLIMIC INC·Filed 2017·Granted Apr 5, 2022·0 cites·5 claims
- 1461US2004205061A1System and method for searching informationNEC CORP·Filed 2004·Application pending·0 cites
- 1560US2004117348A1Sequence display method and homology search method for facilitating access to information relating to regions of mutation and regions of similarity between plurality of sequencesNEC CORP·Filed 2003·Application pending·0 cites
- 1660US2010255020A1Method for inducing cytotoxic t-cells, cytotoxic t-cell inducers, and pharmaceutical compositions and vaccines employing themNEC CORP·Filed 2008·Application pending·0 cites
- 1760US2015087809A1Hla-binding peptides, precursors thereof, dna fragments and recombinant vectors that code for those peptide sequencesMIYAKAWA TOMOYA·Filed 2014·Application pending·0 cites
- 1859US10526388B2Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cellsCYTLIMIC INC·Filed 2016·Granted Jan 7, 2020·0 cites·9 claims
- 1954US2009023895A1Hla-binding peptide, precursor thereof, and dna fragment and recombinant vector coding for said hla-binding peptideNEC CORP·Filed 2007·Application pending·0 cites
- 2053US10537626B2HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cellCYTLIMIC INC·Filed 2015·Granted Jan 21, 2020·0 cites·2 claims
- 2152US2018057531A1Muc1-derived peptide, and pharmaceutical composition for treatment or prevention of cancer, immunity-inducing agent and method for manufacturing antigen presenting cell using sameNEC CORP·Filed 2016·Application pending·0 cites
- 2251US2011060124A1Hla-binding peptides, precursors thereof, dna fragments and recombinant vectors that code for those peptide sequencesNEC CORP·Filed 2010·Application pending·0 cites
- 2351US2008249283A1Hla-Binding Peptides, Precursors Thereof, Dna Fragments and Recombinant Vectors that Code for Those Peptide SequencesMIYAKAWA TOMOYA·Filed 2005·Application pending·0 cites
- 2448US2009144209A1Sequence prediction systemNEC CORP·Filed 2005·Application pending·0 cites
- 2544US2011206711A1Method for inducing cytotoxic t-cells, cytotoxic t-cell inducer, and pharmaceutical composition and vaccine employing sameNEC CORP·Filed 2007·Application pending·0 cites
- 2644US2008306243A1Hla-Binding Peptide, and Dna Fragment and Recombinant Vector Coding for Said Hla-Binding PeptideNEC CORP·Filed 2006·Application pending·0 cites
- 2742US2008293916A1Hla-Binding Peptide, and Dna Fragment and Recombinant Vector Coding for Said Hla-Binding PeptideNEC CORP·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →